The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Results of a randomized, double-blind, placebo-controlled, phase 2 study (OpcemISA) of the combination of ISA101b and cemiplimab versus cemiplimab for recurrent/metastatic (R/M) HPV16-positive oropharyngeal cancer (OPC).
 
Caroline Even
Consulting or Advisory Role - Bristol-Myers Squibb; Fstar Therapeutics (Inst); GlaxoSmithKline (Inst); Innate Pharma; Merck Serono; Merus (Inst); MSD Oncology; Novartis (Inst)
Travel, Accommodations, Expenses - Merck Serono; Merck Serono; MSD Oncology
 
Kevin Joseph Harrington
Honoraria - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Codiak Biosciences (Inst); Inzen Therapeutics (Inst); Johnson and Johnson (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Pfizer (Inst); Replimune (Inst); Scenic Biotech
Consulting or Advisory Role - Arch Oncology (Inst); AstraZeneca (Inst); BMS (Inst); Boehringer Ingelheim (Inst); Inzen Therapeutics (Inst); Merck Serono (Inst); MSD (Inst); Nanobiotix (Inst); Oncolys BioPharma (Inst); Replimune (Inst)
Speakers' Bureau - BMS (Inst); Merck Serono (Inst); MSD (Inst)
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Replimune (Inst)
 
Erminia Massarelli
Honoraria - AstraZeneca; Physicans' Education Resource
Consulting or Advisory Role - Abbvie; Bristol Myers Squibb Foundation; Daiichi-Sankyo; Fusion Pharmaceuticals; Gilead Sciences; Iovance Biotherapeutics; Janssen Scientific Affairs; Mirati Therapeutics; Sanofi
Travel, Accommodations, Expenses - Physicans' Education Resource
 
Marielle Klein Hesselink
Employment - ISA Pharmaceuticals
 
Sonja Visscher
Employment - ISA Pharmaceuticals
 
Matthew G. Fury
Employment - Regeneron; Regeneron (I)
Stock and Other Ownership Interests - Regeneron; Regeneron (I)
Research Funding - Regeneron
Patents, Royalties, Other Intellectual Property - Regeneorn; Regeneron (I)
 
Femke Sanders
Employment - ISA Therapeutics B.V.
 
Simon Laban
Honoraria - Bristol Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Consulting or Advisory Role - Bristol Myers Squibb (Inst); Merck Sharp & Dohme (Inst)
Speakers' Bureau - Merck Sharp & Dohme (Inst)
Patents, Royalties, Other Intellectual Property - Peptides for antigen-specific immunotherapy of head and neck cancer or other cancers (EP2023/071063, patent pending)
 
Jerome Fayette
Honoraria - Bristol-Myers Squibb; Hookipa Pharma; Merck Serono; Merck Sharp & Dohme; Roche
Consulting or Advisory Role - Bristol-Myers Squibb; Elevar Therapeutics; Hookipa Pharma; ITeos Therapeutics; Merck Serono; Merck Sharp & Dohme; Seagen
Research Funding - AstraZeneca (Inst); Bristol-Myers Squibb (Inst)
Travel, Accommodations, Expenses - Bristol-Myers Squibb; Merck Sharp & Dohme
 
Marc Oliva
Honoraria - Bristol-Myers Squibb/Pfizer; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology; Transgene
Consulting or Advisory Role - Merck KGaA; MSD Oncology; MSD Oncology
Research Funding - ALX Oncology (Inst); Bayer (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); GlaxoSmithKline (Inst); ISA Pharmaceuticals (Inst); Merck; MSD Oncology (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst)
Travel, Accommodations, Expenses - BeiGene; Bristol-Myers Squibb/Pfizer; Merck; MSD Oncology
Other Relationship - Merck; MSD Oncology
 
Lisa F. Licitra
Honoraria - Adlai Nortye; ALTIS Omnia Pharma Service S.r.l.; Bristol Mayers Squibb [K.K.]; Merck KGaA; Merck Serono; MSD IT
Consulting or Advisory Role - Abbvie S.r.l.; ALX Oncology; AstraZeneca; Boehringer Ingelheim; Eisai; EMD Ser Reaserach & Development Institute Inc.; Genmab; GlaxoSmithKline; GroupH Ltd; Janssen Research & Development; Merck Healtcare KGaA; Merck Serono; Mirati Therapeutics; MSD; MSD; Novartis Farma S.p.a.; Roche; Seagan
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Celgene (Inst); Debiopharm Group (Inst); Eisai (Inst); Exelixis (Inst); IRX Therapeutics (Inst); Medpace (Inst); Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Roche (Inst); Roche (Inst)
Travel, Accommodations, Expenses - TAE Life Sciences
 
Bohuslav Melichar
Honoraria - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bristol-Myers Squibb; Eisai; Lilly; Merck Serono; MSD; Novartis; Pfizer; Roche
Travel, Accommodations, Expenses - AstraZeneca; Bristol-Myers Squibb/; Merck Serono; MSD
 
Anthony Kong
Honoraria - Avvinity Therapeutics; Bristol-Myers Squibb; Merck; MSD; Puma Biotechnology
Consulting or Advisory Role - Avvinity Therapeutics; Bristol-Myers Squibb; Merck; MSD; Puma Biotechnology
Research Funding - AstraZeneca (Inst); Puma Biotechnology (Inst)
Travel, Accommodations, Expenses - ISA Pharmaceuticals
 
Lot A. Devriese
Honoraria - Bristol Myers Squibb Foundation (Inst); MSD (Inst)
Speakers' Bureau - Nederlandse Internisten Vereniging; Nederlandse Internisten Vereniging
 
Irene Brana
Consulting or Advisory Role - Achilles Therapeutics; Boehringer Ingelheim; Cancer Expert Now; eTheRNA Immunotherapies; Merck Sharp & Dohme; Merus; Sanofi
Speakers' Bureau - Bristol-Myers Squibb; Merck Serono; MSD; Roche
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Celgene (Inst); Debiopharm Group (Inst); GlaxoSmithKline (Inst); Gliknik (Inst); Immutep (Inst); ISA Pharmaceuticals (Inst); Janssen Oncology (Inst); Kura Oncology (Inst); Merck Serono (Inst); Merck Sharp & Dohme (Inst); Merus (Inst); Nanobiotix (Inst); Northern Biologics (Inst); Novartis (Inst); Pfizer (Inst); Regeneron (Inst); Roche (Inst); Seagen (Inst); Seagen (Inst); Shattuck Labs (Inst); Tolremo (Inst); VCN Biosciences (Inst)
Travel, Accommodations, Expenses - MSD Oncology
 
Petra Jankowska
No Relationships to Disclose
 
Marshall R. Posner
Honoraria - Naveris
Consulting or Advisory Role - Aveo; Calliditas Therapeutics; Galeria; Merck; Merus
Research Funding - BioNTech (Inst); Flamingo Pharma (Inst); Gilead Sciences (Inst); Hookipa Pharma (Inst); ISA Pharmaceuticals (Inst); Regeneron (Inst); Toragen (Inst)
Patents, Royalties, Other Intellectual Property - anti-Staphylococcal Monoclonal antibody (Inst); Uptodate editor
(OPTIONAL) Uncompensated Relationships - Frizent; Vivan Therapeutics
 
Leon W. Hooftman
Employment - ISA Pharmaceuticals
Stock and Other Ownership Interests - ISA Pharmaceuticals
Honoraria - ISA Pharmaceuticals
Research Funding - ISA Pharmaceuticals
Travel, Accommodations, Expenses - ISA Pharmaceuticals
 
Cornelis JM Melief
Employment - ISA Pharmaceuticals
Stock and Other Ownership Interests - ISA Pharmaceuticals
Patents, Royalties, Other Intellectual Property - I am holder of 10 approved patents from Leiden University Medical Center. These patents have been licensed to ISA Pharmaceuticals. They will lead to payments to me from the leiden University Medical Center, when the company is bale to market a product bas
 
Renata Ferrarotto
Consulting or Advisory Role - Answers in CME; Coherus Biosciences; Eisai; Elevar Therapeutics; Labcorp Drug Development; Prelude Therapeutics; Regeneron; Remix Therapeutics; Sanofi/Aventis
Research Funding - Ayala Pharmaceuticals (Inst); Gilead Sciences (Inst); ISA Pharmaceuticals (Inst); Merck Serono (Inst); Pfizer/EMD Serono (Inst); Prelude Therapeutics (Inst); Seagen (Inst); Viracta Therapeutics (Inst)
Patents, Royalties, Other Intellectual Property - Royalties on UpToDate chapter on olfactory neuroblastoma, ~ 300 dollars per year